Philip Morris International (PM) is back in focus after the U.S. FDA granted Marketing Granted Orders for 11 ZYN ULTRA moist oral nicotine pouch products, expanding the company’s regulated smoke free portfolio.
See our latest analysis for Philip Morris International.
The FDA approval arrives after a run of steady news from Philip Morris International, including Q2 2026 results that met market expectations and a recent ZYN-branded art initiative in the U.S. While the share price has softened over the past month, with a 30-day share price return of 3.12% and a 7-day share price return of 1.13%, the year-to-date share price return of 17.42% and a 5-year total shareholder return of 132.88% point to momentum that has built over a longer period.
If you are already watching how Philip Morris International is evolving its smoke free portfolio, this can be a useful moment to also scan the wider market through 21 top founder-led companies
The recent pullback sits alongside steady revenue and net income growth at Philip Morris International. Are investors reassessing the business after the ZYN news, or has sentiment simply moved ahead of fundamentals as valuation now gets closer scrutiny?
Philip Morris International's most followed narrative pegs fair value at $203.80, a premium to the last close at $188.23. This sets up a valuation gap investors are watching closely.
The analysts have a consensus price target of $203.8 for Philip Morris International based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $225.0, and the most bearish reporting a price target of just $175.0.
Want to see what sits behind that fair value for Philip Morris International? The narrative leans on steady revenue expansion, rising margins and a richer future earnings multiple. Curious which of these levers carries the most weight in the model.
Result: Fair Value of $203.80 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear watchpoints for Philip Morris International, including any slowdown in ZYN and IQOS momentum, as well as the impact of shifting regulation and taxes.
Find out about the key risks to this Philip Morris International narrative.
With mixed sentiment around Philip Morris International, this is a good time to move fast and judge the balance of risk and reward for yourself. To weigh up both sides in one place, start with the 4 key rewards and 1 important warning sign.
If you want to stay ahead of the crowd, use the Simply Wall Street Screener to uncover fresh stock ideas before they become obvious to everyone else.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com